Navigation Links
Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals
Date:3/24/2009

Reverse Split Ratio of Outstanding Cellegy Common Stock Expected to be Approximately 1: 9.929060

BOYERTOWN, Pa., March 24 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced that the stockholders of both Cellegy and Adamis Pharmaceuticals Corporation approved the previously announced merger of the two companies at stockholder meetings held on March 23, 2009. The transaction, which is subject to customary closing conditions, is expected to close on or about April 1, 2009.

At the Cellegy meeting, the stockholders also approved several proposals related to the merger transaction, including amendments to Cellegy's charter to increase the number of authorized shares of common stock to 175,000,000 shares and of preferred stock to 10,000,000 shares, to change the name of the company to "Adamis Pharmaceuticals Corporation" following the closing of the merger, and to effect a reverse split of the outstanding Cellegy common stock immediately before the closing of the merger.

The ratio of the Cellegy reverse split is expected to be approximately 1:9.929060. As a result, every approximately 9. 929060 shares of Cellegy common stock will be combined into one share of post-reverse split common stock, and the outstanding shares of Cellegy common stock will be converted into 3,000,000 post-reverse split shares. Approximately 42,978,000 post-reverse split shares of common stock are expected to be issued to the former holders of outstanding Adamis shares. The Cellegy common stock will continue to trade on a pre-reverse split basis until the reverse split is approved by the Financial Industry Regulatory Authority (FINRA) and reflected on the OTC Bulletin Board, which is expected to occur shortly after the closing of the merger.

About Cellegy

Cellegy Pharmaceuticals is a specialty biopharmaceutical company. Cellegy has intellectual property relating to a portfolio of proprietary product candidates known as microbicides, including Savvy(R) (C31G vaginal gel), a microbicide gel product for contraception. Savvy was the subject of a Phase 3 clinical study in the United States for contraception. That study has been completed, and the analysis of the results is expected to be completed by the end of the second quarter of 2009.

About Adamis

Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory, and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Any statements in this press release regarding the merger transaction, Cellegy's business and technology, and Adamis' business, technology, products or potential products that are not historical facts may be considered "forward-looking statements," including statements regarding the acquisition, its expected benefits, and the acquisition's anticipated timing. The company has based these forward-looking statements on management's current preliminary expectations, assumptions, estimates and projections. While the company believes its expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. You should also review the company's discussion of risk factors and other disclosures in Cellegy's Annual Report on Form 10-K for the year ended December 31, 2007 and other filings with the Securities and Exchange Commission, including the registration statement on Form S-4 filed by Cellegy with the SEC relating to the merger transaction. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Cellegy Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
2. Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation
3. Flextronics Shareholders and Solectron Stockholders Approve Acquisition
4. ISS Recommends Hologic Stockholders Vote FOR Merger With Cytyc
5. Clarent Hospital Corporation to Make a Cash Distribution to Stockholders
6. Manor Care, Inc. Stockholders Approve Proposed Merger
7. Hologic Stockholders Approve Merger with Cytyc
8. PainCare Announces Results of 2007 Annual Meeting of Stockholders
9. Majority of IsoTis Stockholders Vote for Integra Acquisition
10. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual Fall ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day conference ... practices for third party administrators (TPAs) related to health plan management and compliance, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Big Barker ... for its September 2016 donation of dog beds to the K9 officers of ... and honors for its contribution from city and state officials. , The ...
(Date:9/19/2017)... ... ... The ISO 9001 standard sets out the requirements for a quality management system ... satisfaction. ISO 9001:2015 was released in 2015 and certified organizations have three years to ... , As described in this white paper , ISO 9001:2015 places greater ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to assess ... their cardiovascular disease (CVD) risk in the next 10 years. , Imagine if ... estimated 10-year risk prediction! , Imagine if the weatherman says there is a 7.5% ...
(Date:9/19/2017)... Denver, CO (PRWEB) , ... September 19, 2017 , ... ... young children. Parents and guardians deserve clear instructions on how to keep babies and ... than September, which is Baby Safety Month. , Great Time to Check Labels, Brands ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a ... public.Where:  BTF,s Mobile MRI Unit – a 70 ... D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign ...
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
Breaking Medicine Technology: